Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Long-term follow-up of endocrine and metabolic changes after gestational diabetes

Official title: Long-Term Effects of Gestational Diabetes Mellitus on Postpartum Chronic Non-Communicable Diseases: A Prospective Cohort Study

Run by Peking University First Hospital · NCT07119177 · Data updated 2026-11-12

This project will follow women who had gestational diabetes and their children to see if pregnancy and early-life measurements predict later chronic diseases.

More Gestational Diabetes Mellitus (GDM) trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment800 (estimated)
SponsorPeking University First Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMarch 29, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedAugust 12, 2025
Trial IDNCT07119177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) who registered for antenatal care and delivered at Peking University First Hospital between 2007 and 2016, were diagnosed with GDM by OGTT, and can provide informed consent and attend follow-up visits are ideal candidates.

Probably not a fit

People without complete pregnancy records, those unable to complete follow-up, those not diagnosed with GDM, or individuals who delivered elsewhere are unlikely to gain direct benefit from this cohort's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort will enroll women aged 18 and older who delivered at Peking University First Hospital between 2007 and 2016 and had GDM diagnosed by OGTT. Investigators will combine antenatal records, diagnostic OGTT data, and scheduled long-term follow-ups to track endocrine, metabolic, and clinical outcomes in mothers and their offspring. The project aims to map the natural course of non-communicable chronic diseases after GDM, identify high-risk factors and key mediators, and build predictive models for timing and targets of intervention. No interventional procedures are planned; analyses will be observational and data-driven to inform future prevention strategies.

Why it matters

Potential benefit: If successful, this work could identify mothers and children at high risk for diabetes, obesity, and other chronic diseases and support earlier, more targeted prevention efforts.

How similar studies have gone: Previous cohorts have associated GDM with higher maternal and offspring risk of diabetes and obesity, but large, long-term, high-quality cohorts and validated predictive models remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (≥18 years old) who registered for antenatal care and delivered at Peking University Firest Hospital's obstetrics department between 2007 and 2016.
* Diagnosed with gestational diabetes mellitus (GDM) during pregnancy via an oral glucose tolerance test (OGTT).
* Signed informed consent.

Exclusion Criteria:

* Lack of pregnancy-related obstetric follow-up records.
* Inability to cooperate with and complete subsequent scheduled follow-ups.

Where it's running

  • Peking University First Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.